Frank Bernier on Nature Aging Breakthrough: Urolithin A Just Scored a Big Win for Immune Aging
Frank Bernier, R&D Unit Leader at GLICO, posted on LinkedIn:
”Urolithin A just scored a big win for immune aging.
A new randomized, double-blind, placebo-controlled trial in Nature Aging asked a simple question: if we improve mitochondrial quality, can we make aging immune cells act young again?
Healthy middle-aged adults took Urolithin A (1,000 mg/day) for 4 weeks. The results:
• ↑ Naive-like CD8⁺ T cells
• ↓ Terminally exhausted CD8⁺ T cells
• ↑ Fatty acid oxidation capacity in CD8⁺ T cells
• ↑ Mitochondrial biogenesis in immune cells
• ↑ NK cells and nonclassical monocytes
• Better functional responses (TNF secretion, bacterial uptake)
In other words: tuning mitophagy and mitochondria did not just support immunity in theory. It shifted real human immune cell phenotypes toward a more resilient, “younger” state in weeks.
Longevity is not only about adding years. It is about preserving immune memory, surveillance, and metabolic fitness so the system can still recognise, respond, and repair.
For anyone working in nutrition, microbiome, or healthy aging, this is a strong signal: mitochondria are not a side character. They are a primary target.
Article (Open Access) here.”
Title: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial
Authors: Dominic Denk, Anurag Singh, Herbert G. Kasler, Davide D’Amico, Julia Rey, Lucía Alcober-Boquet, Johanna M. Gorol, Christoph Steup, Ritesh Tiwari, Ryan Kwok, Rafael J. Argüello, Julie Faitg, Kathrin Sprinzl, Stefan Zeuzem, Valentina Nekljudova, Sibylle Loibl, Eric Verdin, Chris Rinsch, Florian R. Greten
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025